It's literally 2016 but worse somehow.

One source close to the Harris campaign tells Rolling Stone they reached out to several staffers in and around the campaign to voice concerns about the candidate embracing Dick and Liz Cheney.

“People don’t want to be in a coalition with the devil,” says the source, speaking about Dick Cheney. They say a Harris staffer responded that it was not the staff’s role to challenge the campaign’s decisions.

A Democratic strategist says they warned key Harris surrogates and top-level officials at the Democratic National Committee that campaigning with Liz Cheney — and making the campaign’s closing argument about how many Republicans were supporting Harris — was highly unlikely to motivate any new swing voters, and risked dissuading already-despondent, infrequent Democratic voters who had supported Biden in 2020. The strategist says they also attempted to have big donors and battleground state party chairs convey the same argument to the Harris campaign.

Another Democratic operative close to Harrisworld says they sent memos and data to Harris campaign staffers underscoring how, among other things, Republican voters, believe it or not, vote Republican — and that the data over the past year screamed that Democrats instead needed to reassure and energize the liberal base and Dem-leaning working class in battleground states. “We were told, basically, to get lost, no thank you,” says the operative.

Occupational stress is a trigger for Rebecca Wilde, a 32-year-old tech worker in Buckinghamshire. Four years ago, work pressures combined with family issues affected her sleep, leading to a severe manic episode. She was hospitalised for a month and a half, and diagnosed with type 1 bipolar disorder, also known as bipolar 1, a mood condition that can have devastating consequences if not managed well. Mania, and sometimes psychosis, is present in type 1.

Wilde was experiencing both: at one point, she thought she could talk to dogs. She was put on the antipsychotic drug olanzapine and another mood stabiliser, lithium. She has now been taking lithium alone for a year, and it has been transformative. “On the lithium, I definitely feel like me,” she says.

While Wilde was transitioning to lithium only, researchers were furiously debating the evidence around the drug. In 2023, the journal Bipolar Disorders published an editorial co-written by editor-in-chief Gin S Malhi, titled “Lithium first: not merely first line”. This asserted that lithium should be considered not only as one of several possible initial treatments for bipolar disorder, but as the first and foremost of these. Lithium “needs to be championed”, maintains Malhi, a visiting psychiatry professor at Oxford University.

This is not the only heated dispute among lithium researchers from the past couple of years. A 2024 critique led to professors trading words such as “pseudoscience” and “extraordinarily venomous”. Feuds such as these point to the high stakes over the declining popularity of lithium.

Medicinal lithium is remarkable. There is more evidence of lithium’s effectiveness in managing bipolar disorder than for any other medicine. As a naturally occurring ion, lithium can’t be patented. And unlike most medicines, it’s not metabolised by the body.

Malhi explains why this is significant: “With lithium, the body can be thought of simply as a bucket of water with input and output of fluid. Then, whatever lithium you add gives you a plasma level. It means we can accurately make changes with sensitivity around plasma levels and clinical response and tolerability.”